

10/580,480

in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:09:21 ON 08 SEP 2010

=> le reg

LE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 14:09:32 ON 08 SEP 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2010 HIGHEST RN 1240243-66-6

DICTIONARY FILE UPDATES: 7 SEP 2010 HIGHEST RN 1240243-66-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10580480.str


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

10/923,271



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss

SAMPLE SEARCH INITIATED 14:10:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1819 TO ITERATE

100.0% PROCESSED 1819 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 33822 TO 38938

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.49

0.71

FILE 'CAPLUS' ENTERED AT 14:10:10 ON 08 SEP 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

10/923,271

FILE COVERS 1907 - 8 Sep 2010 VOL 153 ISS 11  
FILE LAST UPDATED: 7 Sep 2010 (20100907/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAPLUS now includes complete International Patent Classification (IPC)  
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s l2

L3 1 L2

=> d ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 5.81 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:523234 CAPLUS

DOCUMENT NUMBER: 143:59339

TITLE: Preparation of diamine and iminodiacetic acid  
hydroxamic acid derivatives as histone deacetylase  
inhibitors useful against cancer and other diseases

INVENTOR(S): Miller, Thomas A.; Witter, David J.; Belvedere, Sandro

PATENT ASSIGNEE(S): Aton Pharma, Inc., USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053610	A2	20050616	WO 2004-US39221	20041123
WO 2005053610	A3	20051222		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004294930	A2	20050616	AU 2004-294930	20041123
AU 2004294930	A1	20050616		
CA 2547356	A1	20050616	CA 2004-2547356	20041123

EP 1694329	A2	20060830	EP 2004-811866	20041123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1905881	A	20070131	CN 2004-80040991	20041123
JP 2007512367	T	20070517	JP 2006-541622	20041123
IN 2006DN03110	A	20070824	IN 2006-DN3110	20060531
US 20090023718	A1	20090122	US 2008-580480	20080214
PRIORITY APPLN. INFO.:			US 2003-525333P	P 20031126
			WO 2004-US39221	W 20041123

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): CASREACT 143:59339; MARPAT 143:59339

AB The present invention relates to a novel class of hydroxamic acid derivs. having a diamine or iminodiacetic acid backbone (1):  
 $(R1(HNC(O))p1CH2)(R2(HNC(O))p2CH2)N(C(O))m(CH2)nC(O)NHOH$ ;  $n = 2-8$ ;  $m = 0-1$ ;  $p1$  and  $p2 = 0$  or  $1$ ;  $R1$  and  $R2 =$  an (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when  $p1$  and  $p2$  are both  $0$ ,  $R1$  and  $R2$  together with the  $-CH2NCH2-$  group to which they are attached can also be a  $N$ -containing heterocyclic ring; or when at least one of  $p1$  or  $p2$  is not  $0$ ,  $R1$  or  $R2$  or both can also  $= H$  or alkyl; e.g. 6-[bis[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]amino]hexanoic acid hydroxyamide (2)). The hydroxamic acid compds. can be used to treat cancer. The hydroxamic acid compds. can also inhibit histone deacetylase (HDAC) and are suitable for use in selectively including terminal differentiation, arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, 1 are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. Compds. 1 are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compns. comprising the hydroxamic acid derivs., and safe, dosing regimens of these pharmaceutical compns., which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivs. in vivo. Although the methods of preparation are not claimed, example preps. and/or characterization data for .apprx.60 1 are included. For example, 2 was prepared by coupling of 6-[N,N-bis(carboxymethyl)amino]hexanoic acid Me ester hydrochloride with N-phenylpiperazine using EDCI (74 %) followed by conversion of the Me ester to the hydroxamic acid using  $NH_2OH$  (88 %). Results of HDAC inhibition by .apprx.80 examples of 1 are tabulated.

IT 853954-60-6P, Octanedioic acid  
N,N-bis[(cyclohexylcarbamoyl)methyl]amide hydroxyamide  
853954-73-1P, Heptanedioic acid  
N-[(cyclohexylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide hydroxyamide 853954-79-7P, Heptanedioic acid  
N,N-bis[(2-phenoxyphenylcarbamoyl)methyl]amide hydroxyamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of diamine and iminodiacetic acid hydroxamic acid derivs. as histone deacetylase inhibitors useful against cancer and other diseases)


RN 853954-60-6 CAPLUS  
CN Octanediamide, N1,N1-bis[2-(cyclohexylamino)-2-oxoethyl]-N8-hydroxy- (CA INDEX NAME)

10/923,271




RN 853954-73-1 CAPLUS

CN Heptanediamide, N1-[2-(cyclohexylamino)-2-oxoethyl]-N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]- (CA INDEX NAME)



RN 853954-79-7 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-(4-phenoxyphenyl)amino]ethyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.81

7.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.85

-0.85

FILE 'REGISTRY' ENTERED AT 14:11:20 ON 08 SEP 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

TOh

08/09/2010

10/923,271

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2010 HIGHEST RN 1240243-66-6  
DICTIONARY FILE UPDATES: 7 SEP 2010 HIGHEST RN 1240243-66-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s ll sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 14:11:32 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 35574 TO ITERATE

100.0% PROCESSED 35574 ITERATIONS 39 ANSWERS  
SEARCH TIME: 00.00.02

L4 39 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	191.54	199.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'CAPLUS' ENTERED AT 14:11:40 ON 08 SEP 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

10/923,271

FILE COVERS 1907 - 8 Sep 2010 VOL 153 ISS 11  
FILE LAST UPDATED: 7 Sep 2010 (20100907/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAPLUS now includes complete International Patent Classification (IPC)  
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s l4

L5 2 L4

=> d 1-2 ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 11.62 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:666074 CAPLUS

DOCUMENT NUMBER: 151:520134

TITLE: Pharmacophore identification of hydroxamate HDAC 1  
inhibitors

AUTHOR(S): Yu, Liqin; Liu, Fei; Chen, Yadong; You, Qidong

CORPORATE SOURCE: Jiangsu Key Laboratory of Carcinogenesis and  
Intervention, Department of Medicinal Chemistry, China  
Pharmaceutical University, Nanjing, Jiangsu, 210009,  
Peop. Rep. China

SOURCE: Chinese Journal of Chemistry (2009), 27(3), 557-564

CODEN: CJOCEV; ISSN: 1001-604X

PUBLISHER: Shanghai Institute of Organic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A three-dimensional pharmacophore model was established based on 24  
hydroxamate histone deacetylase (HDAC) inhibitors by HypoGen algorithm  
embedded in Catalyst software. The best pharmacophore hypothesis (Hypol),  
consisting of four chemical features (one hydrogen-bond acceptor, one aromatic  
ring and two hydrophobic groups), has a correlation coefficient of 0.946. The  
Hypol was also validated by a test set consisting of 20 other compds.  
Compared with the prior studies towards HDAC inhibitors the detailed chemical  
features of the "CAP" region in the reported HDAC inhibitors were for the  
first time depicted, which would be helpful in the further designing of  
novel HDAC inhibitors.

IT 853954-78-6 853954-80-0 853954-87-7


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)

(three-dimensional pharmacophore model was developed based on  
hydroxamate deacetylase 1 inhibitors by HypoGen algorithm embedded in  
catalyst software, suggests that branched cap structure of HDAC  
inhibitors strengthen interaction to HDAC 1)

RN 853954-78-6 CAPLUS


10/923,271

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(trifluoromethyl)phenyl]amino]ethyl]- (CA INDEX NAME)




RN 853954-80-0 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[[4-(4-morpholinyl)phenyl]amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-87-7 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[(6-methoxy-2-benzothiazolyl)amino]-2-oxoethyl]- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:523234 CAPLUS

DOCUMENT NUMBER: 143:59339

TITLE: Preparation of diamine and iminodiacetic acid hydroxamic acid derivatives as histone deacetylase inhibitors useful against cancer and other diseases

INVENTOR(S): Miller, Thomas A.; Witter, David J.; Belvedere, Sandro

PATENT ASSIGNEE(S): Aton Pharma, Inc., USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053610	A2	20050616	WO 2004-US39221	20041123
WO 2005053610	A3	20051222		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004294930	A2	20050616	AU 2004-294930	20041123
AU 2004294930	A1	20050616		
CA 2547356	A1	20050616	CA 2004-2547356	20041123
EP 1694329	A2	20060830	EP 2004-811866	20041123
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1905881	A	20070131	CN 2004-80040991	20041123
JP 2007512367	T	20070517	JP 2006-541622	20041123
IN 2006DN03110	A	20070824	IN 2006-DN3110	20060531
US 20090023718	A1	20090122	US 2008-580480	20080214
PRIORITY APPLN. INFO.:			US 2003-525333P	P 20031126
			WO 2004-US39221	W 20041123

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:59339; MARPAT 143:59339

AB The present invention relates to a novel class of hydroxamic acid derivs. having a diamine or iminodiacetic acid backbone (1: (R1(HNC(O))p1CH2)(R2(HNC(O))p2CH2)N(C(O))m(CH2)nC(O)NHOH; n = 2-8; m = 0-1; p1 and p2 = 0 or 1; R1 and R2 = an (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when p1 and p2 are both 0, R1 and R2 together with the -CH2NCH2- group to which they are attached can also be a N-containing heterocyclic ring; or when at least one of p1 or p2 is not 0, R1 or R2 or both can also = H or alkyl; e.g. 6-[bis[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]amino]hexanoic acid hydroxyamide (2)). The hydroxamic acid compds. can be used to treat cancer. The hydroxamic acid compds. can also inhibit histone deacetylase (HDAC) and are suitable for use in selectively including terminal differentiation, arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, 1 are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. Compds. 1 are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compns. comprising the hydroxamic acid derivs., and safe, dosing regimens of these pharmaceutical compns., which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivs. in vivo. Although the methods of preparation are not claimed, example preps. and/or

characterization data for .apprx.60 1 are included. For example, 2 was prepared by coupling of 6-[N,N-bis(carboxymethyl)amino]hexanoic acid Me ester hydrochloride with N-phenylpiperazine using EDCI (74 %) followed by conversion of the Me ester to the hydroxamic acid using NH<sub>2</sub>OH (88 %). Results of HDAC inhibition by .apprx.80 examples of 1 are tabulated.

IT 853954-53-7P, Octanedioic acid  
 N,N-bis[(quinolin-8-ylcarbamoyl)methyl]amide hydroxyamide  
 853954-55-9P, Hexanedioic acid  
 N,N-bis[(quinolin-8-ylcarbamoyl)methyl]amide hydroxyamide  
 853954-56-0P, Heptanedioic acid  
 N,N-bis[(quinolin-8-ylcarbamoyl)methyl]amide hydroxyamide  
 853954-57-1P, Heptanedioic acid  
 N,N-bis[(phenylcarbamoyl)methyl]amide hydroxyamide 853954-58-2P  
 , Octanedioic acid N,N-bis[(benzylcarbamoyl)methyl]amide hydroxyamide  
 853954-59-3P, Octanedioic acid  
 N,N-bis[(phenethylcarbamoyl)methyl]amide hydroxyamide  
 853954-60-6P, Octanedioic acid  
 N,N-bis[(cyclohexylcarbamoyl)methyl]amide hydroxyamide  
 853954-61-7P, Octanedioic acid  
 N,N-bis[(4-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide  
 853954-62-8P, Octanedioic acid  
 N,N-bis[(3-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide  
 853954-63-9P, Octanedioic acid  
 N,N-bis[(quinolin-6-ylcarbamoyl)methyl]amide hydroxyamide  
 853954-64-0P, Heptanedioic acid  
 N,N-bis[(benzylcarbamoyl)methyl]amide hydroxyamide 853954-65-1P  
 , Heptanedioic acid N,N-bis[(phenethylcarbamoyl)methyl]amide hydroxyamide  
 853954-66-2P, Heptanedioic acid  
 N,N-bis[(cyclohexylcarbamoyl)methyl]amide hydroxyamide  
 853954-67-3P, Heptanedioic acid  
 N,N-bis[(4-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide  
 853954-68-4P, Heptanedioic acid  
 N,N-bis[(3-benzyloxyphenylcarbamoyl)methyl]amide hydroxyamide  
 853954-69-5P, Heptanedioic acid  
 N,N-bis[[ (benzothiazol-2-yl)carbamoyl]methyl]amide hydroxyamide  
 853954-70-8P, Heptanedioic acid  
 N,N-bis[(quinolin-6-ylcarbamoyl)methyl]amide hydroxyamide  
 853954-71-9P, Heptanedioic acid  
 N-[(benzylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide hydroxyamide  
 853954-72-0P, Heptanedioic acid hydroxyamide  
 N-[(phenethylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide  
 853954-73-1P, Heptanedioic acid  
 N-[(cyclohexylcarbamoyl)methyl]-N-[(phenylcarbamoyl)methyl]amide  
 hydroxyamide 853954-74-2P, Heptanedioic acid hydroxyamide  
 N-[(phenylcarbamoyl)methyl]-N-[(quinolin-8-ylcarbamoyl)methyl]amide  
 853954-75-3P, Heptanedioic acid  
 N,N-bis[(4-fluorophenylcarbamoyl)methyl]amide hydroxyamide  
 853954-76-4P, Heptanedioic acid  
 N,N-bis[[ (2,3-dihydrobenzo[1,4]dioxin-6-yl)carbamoyl]methyl]amide  
 hydroxyamide 853954-77-5P, Heptanedioic acid  
 N,N-bis[(1H-indazol-5-ylcarbamoyl)methyl]amide hydroxyamide  
 853954-78-6P, Heptanedioic acid  
 N,N-bis[[ (4-trifluoromethylphenyl)carbamoyl]methyl]amide hydroxyamide  
 853954-79-7P, Heptanedioic acid  
 N,N-bis[(2-phenoxyphenylcarbamoyl)methyl]amide hydroxyamide  
 853954-80-0P, Heptanedioic acid

N,N-bis[[[4-(morpholin-4-yl)phenyl]carbamoyl]methyl]amide hydroxyamide  
853954-81-1P, Heptanedioic acid

N,N-bis[[[4-[(4-tolylsulfonyl)amino]phenyl]carbamoyl]methyl]amide  
hydroxyamide 853954-82-2P, Heptanedioic acid

N,N-bis[(benzodioxol-5-ylcarbamoyl)methyl]amide hydroxyamide  
853954-83-3P, Heptanedioic acid

N,N-bis[(3-phenoxyphenylcarbamoyl)methyl]amide hydroxyamide  
853954-84-4P, Heptanedioic acid

N,N-bis[(9H-fluoren-2-ylcarbamoyl)methyl]amide hydroxyamide  
853954-85-5P, Heptanedioic acid

N,N-bis[(4-tert-butylphenylcarbamoyl)methyl]amide hydroxyamide  
853954-86-6P, Heptanedioic acid

N,N-bis[[[2-(1H-indol-3-yl)ethyl]carbamoyl]methyl]amide hydroxyamide  
853954-87-7P, Heptanedioic acid

N,N-bis[(6-methoxybenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide  
853954-88-8P, Heptanedioic acid

N,N-bis[(6-chlorobenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide  
853954-89-9P, Heptanedioic acid

N,N-bis[(4-methylbenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide  
853954-90-2P, Heptanedioic acid

N,N-bis[(indan-1-ylcarbamoyl)methyl]amide hydroxyamide  
853954-91-3P, Heptanedioic acid

N,N-bis[[[1-methyl-1H-benzimidazol-2-yl]carbamoyl]methyl]amide  
hydroxyamide 853954-92-4P, Heptanedioic acid


N,N-bis[(6-fluorobenzothiazol-2-ylcarbamoyl)methyl]amide hydroxyamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of diamine and iminodiacetic acid hydroxamic  
acid derivs. as histone deacetylase inhibitors useful against cancer  
and other diseases)

RN 853954-53-7 CAPLUS


CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-(8-quinolinylamino)ethyl]-  
(CA INDEX NAME)



RN 853954-55-9 CAPLUS


CN Hexanediamide, N6-hydroxy-N1,N1-bis[2-oxo-2-(8-quinolinylamino)ethyl]-  
(CA INDEX NAME)

10/923,271




RN 853954-56-0 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-(8-quinolinylamino)ethyl]-  
(CA INDEX NAME)



RN 853954-57-1 CAPLUS


CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-(phenylamino)ethyl]- (CA  
INDEX NAME)




RN 853954-58-2 CAPLUS

CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[(phenylmethyl)amino]ethyl]-  
(CA INDEX NAME)


10/923,271




RN 853954-59-3 CAPLUS  
 CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[(2-phenylethyl)amino]ethyl]-  
 (CA INDEX NAME)



RN 853954-60-6 CAPLUS  
 CN Octanediamide, N1,N1-bis[2-(cyclohexylamino)-2-oxoethyl]-N8-hydroxy- (CA  
 INDEX NAME)




RN 853954-61-7 CAPLUS  
 CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[[4-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)




RN 853954-62-8 CAPLUS  
 CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-[[3-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)

10/923,271




RN 853954-63-9 CAPLUS

CN Octanediamide, N8-hydroxy-N1,N1-bis[2-oxo-2-(6-quinolinylamino)ethyl]-  
(CA INDEX NAME)




RN 853954-64-0 CAPLUS

CN    Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(phenylmethyl)amino]ethyl]-  
       (CA INDEX NAME)



RN 853954-65-1 CAPLUS


CN     Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(2-phenylethyl)amino]ethyl]-  
           (CA INDEX NAME)



RN 853954-66-2 CAPLUS


CN	Heptanediamide, N1,N1-bis[2-(cyclohexylamino)-2-oxoethyl]-N7-hydroxy- (INDEX NAME)	(CA
----	---	-----

10/923,271




RN 853954-67-3 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)




RN 853954-68-4 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[3-(phenylmethoxy)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-69-5 CAPLUS

CN Heptanediamide, N1,N1-bis[2-(2-benzothiazolylamino)-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)




RN 853954-70-8 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-(6-quinolinylamino)ethyl]-


10/923,271

(CA INDEX NAME)




RN 853954-71-9 CAPLUS

CN Heptanediamide, N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]-N1-[2-oxo-2-[(phenylmethyl)amino]ethyl]- (CA INDEX NAME)




RN 853954-72-0 CAPLUS

CN Heptanediamide, N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]-N1-[2-oxo-2-[(2-phenylethyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-73-1 CAPLUS

CN Heptanediamide, N1-[2-(cyclohexylamino)-2-oxoethyl]-N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]- (CA INDEX NAME)




RN 853954-74-2 CAPLUS




10/923,271

CN Heptanediamide, N7-hydroxy-N1-[2-oxo-2-(phenylamino)ethyl]-N1-[2-oxo-2-(8-quinolinylamino)ethyl]- (CA INDEX NAME)




RN 853954-75-3 CAPLUS

CN Heptanediamide, N1,N1-bis[2-[(4-fluorophenyl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-76-4 CAPLUS


CN Heptanediamide, N1,N1-bis[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-77-5 CAPLUS


CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-(1H-indazol-5-ylamino)-2-oxoethyl]- (CA INDEX NAME)

10/923,271




RN 853954-78-6 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(trifluoromethyl)phenyl]amino]ethyl]- (CA INDEX NAME)




RN 853954-79-7 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(phenoxy)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 853954-80-0 CAPLUS


CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (CA INDEX NAME)




RN 853954-81-1 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[[4-[[[4-(methylphenyl)sulfonyl]amino]phenyl]amino]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 853954-82-2 CAPLUS

CN Heptanediamide, N1,N1-bis[2-(1,3-benzodioxol-5-ylamino)-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-83-3 CAPLUS


CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-oxo-2-[(3-phenoxyphenyl)amino]ethyl]- (CA INDEX NAME)



RN 853954-84-4 CAPLUS


CN Heptanediamide, N1,N1-bis[2-(9H-fluoren-2-ylamino)-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)

10/923,271




RN 853954-85-5 CAPLUS

CN Heptanediamide, N1,N1-bis[2-[[4-(1,1-dimethylethyl)phenyl]amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-86-6 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[[2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)




RN 853954-87-7 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[[6-methoxy-2-benzothiazolyl]amino]-2-oxoethyl]-


10/923,271

2-oxoethyl]- (CA INDEX NAME)




RN 853954-88-8 CAPLUS

CN Heptanediamide, N1,N1-bis[2-[(6-chloro-2-benzothiazolyl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



RN 853954-89-9 CAPLUS


CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[(4-methyl-2-benzothiazolyl)amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-90-2 CAPLUS



CN Heptanediamide, N1,N1-bis[2-[(2,3-dihydro-1H-inden-1-yl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)

10/923,271




RN 853954-91-3 CAPLUS

CN Heptanediamide, N7-hydroxy-N1,N1-bis[2-[(1-methyl-1H-benzimidazol-2-yl)amino]-2-oxoethyl]- (CA INDEX NAME)



RN 853954-92-4 CAPLUS

CN Heptanediamide, N1,N1-bis[2-[(6-fluoro-2-benzothiazolyl)amino]-2-oxoethyl]-N7-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)